ReviewPreventive medicine reports2025
HIV pre-exposure prophylaxis in Latin America: Public policies, healthcare systems and human rights.
Review in Preventive medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Latin America and the Caribbean: Challenges and Opportunities for HIV Treatment and Prevention.Journal of the International AIDS Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In concentrated HIV epidemics, combination prevention is recommended for key populations, including pre-exposure prophylaxis (PrEP). Our study analyzes PrEP's integration as a public policy in Spanish, Portuguese and French-speaking Latin American countries. Methods: We reviewed documents published through December 2024 from Ministries of Health, international organizations, relevant non-governmental organizations, and collected data on countries' human development index (HDI), healthcare system organization/expenditures, assessing compliance with human rights standards. Results: PrEP policies are described in 16 out of 20 countries reviewed. In Argentina, Brazil, Chile, Colombia, Cuba, El Salvador, Haiti, Mexico and Peru, PrEP is provided to key populations. In Costa Rica, Guatemala, Panama and Paraguay, PrEP is available through research or pilot projects. In the Dominican Republic, Ecuador, and Honduras, PrEP is being scaled up, but specifics remain unclear. Other countries have limited access to PrEP or no available information. Broad PrEP distribution occurs generally in countries with higher healthcare expenditures relative to gross domestic product and high HDI. However, its distribution free of charge is not correlated with universal access to public healthcare. Attention to human rights standards was noted in policies from Argentina, Brazil, Chile, Cuba, Ecuador, El Salvador, Haiti, Mexico, Peru and Uruguay, covering rights to healthcare access, information, informed decision-making, participation, equality, privacy, accountability, and benefits of scientific progress. Conclusions: As of December 2024, PrEP policies exist in some Latin American countries, but are limited or unavailable in others. Achieving universal healthcare and adhering to human rights norms can improve access/use of this essential HIV prevention tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.